Efficacy of Omalizumab in children with moderate and severe allergic asthma and chronic sinusitis
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
维普
目的 探讨奥马珠单抗在儿童中重度变应性哮喘合并慢性鼻窦炎治疗中的疗效.方法 分析 2020 年 9 月至 2022 年 4月间使用奥马珠单抗治疗的儿童中重度变应性哮喘合并慢性鼻窦炎的临床资料,比较治疗前后儿童哮喘控制评分(childhood asthma control test,C-ACT)、呼出气一氧化氮(fractional concentration of exhaled nitric oxide,FeNO)浓度、第1 秒用力呼气量占预计值百分比(first second percentage to predicted value,FEV1%pred)和小气道功能指标等肺功能检查的变化以及患儿慢性鼻窦炎症状改善情况.结果 完成治疗随访的患儿共 26 例.奥马珠单抗治疗 16 周后患儿哮喘症状及肺功能均改善,C-ACT从(15.57±3.25)分升至(24.98±5.21)分(F=15.711 2,P<0.001);FeNO从(31.55±15.57)ppb降至(19.86±9.80)ppb(F= 4.4265,P=0.0022);肺功能提示FEV1%pred、1 秒率(FEV1/FVC)均升高,但差异无统计学意义(P=0.995 4,P=0.938 2);用力呼气峰流量占预计值百分比、呼出 75%肺活量时的最大呼气流量占预计值百分比、呼出 50%肺活量时的最大呼气流量占预计值百分比均升高,差异有统计学意义(P=0.0477,P=0.0005,P<0.001).患儿鼻窦炎症状显著改善,选择视觉模拟量表评分从(6.40±2.98)分降至(0.85±0.40)分(t=27.2419,P<0.001).结论 奥马珠单抗可改善中重度变应性哮喘合并慢性鼻窦炎患儿的哮喘与鼻窦炎的临床表现、肺功能及生活质量.
Objective To investigate the efficacy of Omalizumab in the treatment of children with moderate to severe allergic asthma and chronic sinusitis.Methods The clinical data of children with moderate and severe allergic asthma and chronic sinusitis treated with Omalizumab from September 2020 to April 2022 were retrospectively analyzed.A comparison was performed on the changes of childhood asthma control test(C-ACT),fractional concentration of exhaled nitric oxide(FeNO),forced expiratory volume in the first second percentage to predicted value(FEV1%pred)and small airway function,the improvement of chronic sinusitis symp-toms,before and after treatment with Omalizumab.Results A total of 26 children completed treatment and follow-up.After 16 weeks of Omalizumab treatment,asthma symptoms and lung function were improved.Compared to pre-treatment,the C-ACT score increased from(15.57±3.25)score to(24.98±5.21)score(F=15.711 2,P<0.001)and FeNO decreased from(31.55±15.57)ppb to(19.86±9.80)ppb(F=4.426 5,P=0.002 2).Lung function indicators showed that FEV1%pred and FEV1/forced vital capacity(FEV1/FVC)increased post-treatment,but the differences were not statistically significant(P=0.9954,P=0.9382).The maximal expiratory flow percentage of the predicted value,forced expiratory flow at 75%to predicted value,forced expiratory flow at 50%to predicted value all increased significantly(P=0.0477,P=0.000 5,P<0.001).The symptoms of sinusitis were also sig-nificantly improved,and the visual analogue scale score increased from 6.40±2.98 pre-treatment to 0.85±0.40 post-treatment(t= 27.2419,P<0.001).Conclusion Omalizumab can significantly improve the clinical symptoms,lung function indicators and quali-ty of life of children with moderate and severe allergic asthma and chronic sinusitis.
OmalizumabAllergic asthmaChronic sinusitisLung function
NETL
NSTL
万方数据
维普
